Physician profile
Samuel Holdiness
NPI 1942595202
$5,571.22
in general payments reported to CMS, 2019-2025
28 companies · $91.43 in 2025
The $91.43 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $828 · 2021: $876 · 2022: $1,291 · 2023: $1,333 · 2024: $57.70 · 2025: $91.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $919.56 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $908.63 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $733.46 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $707.80 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $541.19 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.27 | 2019-2023 | Ofev |
| Pfizer INC. | $291.49 | 2019-2021 | |
| Lilly USA, LLC | $233.00 | 2019-2023 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.19 | 2019-2023 | Xifaxan |
| Amgen INC. | $115.54 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $111.63 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $72.07 | 2023 | Rexulti |
| Allergan, INC. | $61.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.31 | 2019-2021 | |
| Dexcom, INC. | $41.63 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.66 | 2019 | |
| Medtronic, INC. | $34.61 | 2023 | Intellis Adaptivestim, Interstim |
| Mylan Specialty L.P. | $34.60 | 2019-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $31.51 | 2022-2023 | |
| Lundbeck LLC | $29.70 | 2025 | Rexulti |
| Astellas Pharma US INC | $25.54 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $25.50 | 2019 | |
| Abbott Laboratories | $17.23 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $17.01 | 2023 | Gemtesa |
| Inari Medical, INC. | $14.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Teva Pharmaceuticals USA, INC. | $13.36 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Holdiness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.